An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
Bausch + Lomb has received European CE Mark approval for its LuxLife full range of vision intraocular lens (IOL), which offers natural, continuous vision from distance to near. This approval underscores the company’s commitment to providing cataract surgeons with a variety of lens options, following recent product launches in the U.S., Canada, and Europe. The LuxLife IOL, featuring advanced Pure Refractive Optics and Allied Ray Technology, ensures high patient satisfaction and spectacle independence, and will soon be available in Europe, with further regulatory submissions underway.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall score reflects solid revenue growth and a strong gross margin, but significant challenges in profitability and cash flow. Technical analysis shows bearish trends, while valuation metrics indicate poor earnings performance. The earnings call provided some optimism with growth in key segments, though risks remain from Pharmaceuticals and tariff pressures.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb is a global eye health company dedicated to enhancing vision for people worldwide. With a comprehensive portfolio of around 400 products, including contact lenses, eye care products, and ophthalmic surgical devices, the company has a significant presence in research, development, and manufacturing across approximately 100 countries. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey.
Average Trading Volume: 837,966
Technical Sentiment Signal: Sell
Current Market Cap: $3.85B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.